New radioactive tracer could sharpen breast cancer scans

NCT ID NCT05226663

Ongoing Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a new radioactive tracer called [18F]FluorThanatrace can improve PET/CT scans in 36 people with breast cancer. The tracer is designed to highlight an enzyme linked to cancer growth. Participants will receive the tracer before their standard surgery or biopsy, and researchers will compare the scan results with tissue samples to see if the tracer accurately spots cancer activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]FluorThanatrace (a radioactive tracer)
What this could lead to: If successful, this could lead to a more precise imaging method to detect breast cancer activity, helping doctors tailor treatments.
What could go wrong: This is a small, early-phase trial with only 36 participants. The tracer may not reliably show enzyme activity in all patients, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CARCINOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States
Siteman Cancer Center at Washington University

St Louis, Missouri, 63110, United States
University of Pennsylvania/Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.